ALSO NOTED: Pfizer expanding German plant; Actonel gets FDA nod; Humira wins expanded approval; and much more

> Pfizer said it has decided to expand its plant in New Ulm, Germany, to handle manufacturing its worldwide supply of an osteoporosis drug. Story

> P&G, Sanofi Aventis get FDA nod to package once-a-week osteoporosis drug Actonel with six calcium tablets. Release

> EU regulators give Abbott Laboratories expanded approval to market Humira for earlier forms of rheumatoid arthritis and for psoriatic arthritis. Report

> Allon Therapeutics arranged a $6.2 million private placement, the proceeds of which will fund development of two clinical-stage products, an Alzheimer's treatment in Phase I trials, and a drug for cognitive impairment after cardiac bypass surgery, set to start Phase I trials. Story

> Cita Neuro Pharmaceuticals has put off its IPO in favor of negotiations to be acquired by an "international pharmaceutical company," its CEO announced Monday. Release

> Merck today won FDA approval to use its VAQTA hepatitis A vaccine in children as young as 12 months; it previously was approved only in children two years and older. Release

> In face of legal restrictions, some drug makers retire pseudoephedrine-based decongestants; others plan to continue making them. Story

And Finally... Washington, DC-area real estate developers plot research labs, biotech offices, a business incubator, and more adjacent to the FDA's new 3 million sq.ft. campus. Article

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.